High-Intensity Statin Doses
High-intensity statin therapy is defined as atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily, with these doses expected to lower LDL-C by ≥50%. 1
Specific Dosing by Agent
According to the 2018 ACC/AHA Cholesterol Guidelines, high-intensity statins include:
Atorvastatin
- 40 mg daily (evaluated in one RCT as down-titration)
- 80 mg daily (primary dose evaluated in multiple RCTs)
Rosuvastatin
- 20 mg daily (evaluated in RCTs including JUPITER)
- 40 mg daily (parenthetical dose, less commonly used)
Key Clinical Context
These doses were specifically evaluated in randomized controlled trials demonstrating reduction in major cardiovascular events, which is why they appear in boldface in the guideline tables. 1 The FDA labeling confirms rosuvastatin 20 mg achieves approximately 55% LDL-C reduction and rosuvastatin 40 mg achieves approximately 63% reduction. 2
Important Caveats
- Individual response varies: While these doses achieve ≥50% LDL-C reduction across populations, individual patients may respond differently 1
- Simvastatin 80 mg is NOT recommended: Although it lowers LDL-C ≥50%, the FDA specifically advises against initiating or titrating to simvastatin 80 mg due to increased myopathy and rhabdomyolysis risk 1
- Atorvastatin 40 mg has limited evidence: Only one RCT (IDEAL study) evaluated this dose as a down-titration strategy; atorvastatin 80 mg has stronger evidence 1
Practical Application
When prescribing high-intensity statins, start with atorvastatin 80 mg or rosuvastatin 20 mg as these have the most robust evidence from cardiovascular outcomes trials. 1 Rosuvastatin 20 mg was used in JUPITER and demonstrated 44% relative risk reduction in major CV events with 50% median LDL-C reduction. 2